Michael Patterson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michael Patterson has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Nestor Tomycz
Department of Neurosurgery, Allegheny Health Network, Pittsburgh, United States
3 shared publications - Stephen Jaffee
Department of Neurosurgery, Allegheny Health Network, Pittsburgh, United States
2 shared publications - Chinelo Onyiah
Department of Neurosurgery, Allegheny Health Network, Pittsburgh, United States
1 shared publication - Dmytro Iovenko
College of Medicine, Drexel University, Philadelphia, Pennsylvania, United States
1 shared publication - Griffin White
Department of Neurosurgery, Allegheny Health Network, Pittsburgh, United States
1 shared publication - Mokshal H. Porwal
Department of Neurosurgery, Allegheny Health Network, Pittsburgh, PA, USA
1 shared publication
Latest Publications
- Open Access
- 29 May 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 324
BurstDR spinal cord stimulation for chronic regional pain syndrome secondary to Castleman’s disease treatment: A case report
Background: Castleman’s disease is a rare lymphoproliferative disorder that can affect lymph nodes anywhere in the body. Removal of the enlarged lymph nodes may lead to secondary nerve damage, potentially resulting in patients developing complex regional pain syndrome (CRPS) type 2. Spinal cord stimulation (SCS) is a well-established, cost-effective therapy for chronic refractory pain, including CRPS type 2. Case Description: A 32-year-old female who was treated for unicentric hyaline vascular type Castleman’s disease. Following neurolysis, she developed CRPS type 2 of the lumbosacral plexus; her symptoms persisted despite pharmacotherapy and physical therapy. She underwent a trial of burst SCS with significant symptom relief, followed by permanent implantation of a Penta paddle lead at the T8 level. Three months postoperatively, she reported marked clinical improvement and was able to discontinue pregabalin. Conclusion: A 32-year-old female with Castleman’s disease developed CRPS type 2 secondary to neurolysis that was effectively treated with Burst SCS.
- 29 May 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 324
Open AccessBurstDR spinal cord stimulation for chronic regional pain syndrome secondary to Castleman’s disease treatment: A case report
Background: Castleman’s disease is a rare lymphoproliferative disorder that can affect lymph nodes anywhere in the body. Removal of the enlarged lymph nodes may lead to secondary nerve damage, potentially resulting in patients developing complex regional pain syndrome (CRPS) type 2. Spinal cord stimulation (SCS) is a well-established, cost-effective therapy for chronic refractory pain, including CRPS type 2. Case Description: A 32-year-old female who was treated for unicentric hyaline vascular type Castleman’s disease. Following neurolysis, she developed CRPS type 2 of the lumbosacral plexus; her symptoms persisted despite pharmacotherapy and physical therapy. She underwent a trial of burst SCS with significant symptom relief, followed by permanent implantation of a Penta paddle lead at the T8 level. Three months postoperatively, she reported marked clinical improvement and was able to discontinue pregabalin. Conclusion: A 32-year-old female with Castleman’s disease developed CRPS type 2 secondary to neurolysis that was effectively treated with Burst SCS.
- Open Access
- 10 October 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 430
BurstDR spinal cord stimulation for chronic inflammatory demyelinating polyneuropathy
Background: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder in which the immune system attacks the myelin sheath, leading to progressive muscle weakness and sensory loss. Neuropathic pain is a common and often debilitating symptom in patients with CIDP. Treatment options include immunoglobulin therapy and, in refractory cases, spinal cord stimulation (SCS). Case Description: We present the case of a 70-year-old male with CIDP who experienced severe neuropathic pain in a stocking distribution affecting both lower extremities. He had previously been treated with intravenous immunoglobulin with limited relief of his pain symptoms. Due to persistent, debilitating neuropathic pain despite ongoing immunotherapy, he underwent implantation of a thoracic paddle spinal cord stimulator. At 3-month postoperative follow-up, he reported a 75% reduction in pain intensity. Conclusion: BurstDR paddle lead SCS may offer significant pain relief in patients with CIDP-associated neuropathic pain and should be considered as part of a multidisciplinary treatment.
- 10 October 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 430
Open AccessBurstDR spinal cord stimulation for chronic inflammatory demyelinating polyneuropathy
Background: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder in which the immune system attacks the myelin sheath, leading to progressive muscle weakness and sensory loss. Neuropathic pain is a common and often debilitating symptom in patients with CIDP. Treatment options include immunoglobulin therapy and, in refractory cases, spinal cord stimulation (SCS). Case Description: We present the case of a 70-year-old male with CIDP who experienced severe neuropathic pain in a stocking distribution affecting both lower extremities. He had previously been treated with intravenous immunoglobulin with limited relief of his pain symptoms. Due to persistent, debilitating neuropathic pain despite ongoing immunotherapy, he underwent implantation of a thoracic paddle spinal cord stimulator. At 3-month postoperative follow-up, he reported a 75% reduction in pain intensity. Conclusion: BurstDR paddle lead SCS may offer significant pain relief in patients with CIDP-associated neuropathic pain and should be considered as part of a multidisciplinary treatment.
- Open Access
- 23 February 2024
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 15, 60
Successful relief of central poststroke pain with BurstDR spinal cord stimulation: A case series
Background: Central poststroke pain (CPSP) is a commonly undertreated condition that can negatively impact a patient’s quality of life. The efficacy of spinal cord stimulation (SCS) for the treatment of CPSP is not established due to limited studies. Case Description: Here, two patients, ages 42 and 75, sustained strokes resulting in CPSP. After failed medical management, both underwent placement of paddle-lead SCS systems utilizing BurstDR stimulation that successfully resulted in pain resolution. Conclusion: Two patients with CPSP were successfully treated with paddle lead SCS with BurstDR programming.
- 23 February 2024
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 15, 60
Open AccessSuccessful relief of central poststroke pain with BurstDR spinal cord stimulation: A case series
Background: Central poststroke pain (CPSP) is a commonly undertreated condition that can negatively impact a patient’s quality of life. The efficacy of spinal cord stimulation (SCS) for the treatment of CPSP is not established due to limited studies. Case Description: Here, two patients, ages 42 and 75, sustained strokes resulting in CPSP. After failed medical management, both underwent placement of paddle-lead SCS systems utilizing BurstDR stimulation that successfully resulted in pain resolution. Conclusion: Two patients with CPSP were successfully treated with paddle lead SCS with BurstDR programming.